Loading company…
Nanobiotix develops cancer therapies, including a radio enhancer designed to improve radiotherapy for solid tumors.
Founded in 2003 and based in Paris, France, Nanobiotix develops cancer treatments, with a focus on NBTXR3, a radio enhancer intended to increase radiotherapy effects in tumor cells while limiting harm to healthy tissue. Its development work includes cancers of the head, neck, and lung. In May 2026, the company raised EUR 85 million in PIPE funding from Invus Financial Advisors and Qatar Holding LLC. Founder and CEO Laurent Levy leads the company, which planned to use the funds for operating costs and working capital through 2029.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in